![John Clarke](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Clarke
Director/Board Member at ATYR PHARMA, INC.
Net worth: 34 249 $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Schimmel | M | 83 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 22 years |
Sanjay Shukla | M | 52 | 8 years | |
Yvonne Greenstreet | M | 61 | 8 years | |
Jesse E. Ambrosina | M | - |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 12 years |
John J. Park | M | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 27 years |
Tim Coughlin | M | 57 | 7 years | |
Amy Schulman | F | 63 | 10 years | |
Phillip Sharp | M | 79 | 22 years | |
Michael Bonney | M | 65 | 10 years | |
James Bradley | M | - |
Cureatr, Inc.
![]() Cureatr, Inc. Medical/Nursing ServicesHealth Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | 6 years |
Akshay Vaishnaw | M | 61 | 18 years | |
Nancy Krueger | F | 56 | 10 years | |
David Pyott | M | 70 | 9 years | |
Sara Nochur | M | 63 | 18 years | |
Timothy J. Maines | M | - | 7 years | |
Leslie Nangle | M | - | - | |
Christine Regan Lindenboom | F | 43 | 9 years | |
Jane Gross | M | 67 | 5 years | |
Kevin Fitzgerald | M | 56 | 19 years | |
Jorgen Bundgaard Hansen | M | 57 |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 4 years |
Colleen Reitan | F | 64 | 6 years | |
Margaret Hamburg | M | 68 | 5 years | |
Tom McKinley | M | 72 |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 16 years |
Dennis Ausiello | M | 78 | 12 years | |
Kent S. Marquardt | M | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 6 years |
Sara Zaknoen | M | 65 | 3 years | |
Ashlee Dunston | F | - | 4 years | |
Robert W. Ashworth | M | - | 3 years | |
Jim Glasheen | M | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Vasant Jadhav | M | - | 10 years | |
Bharath Ganesan | M | - |
Cureatr, Inc.
![]() Cureatr, Inc. Medical/Nursing ServicesHealth Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | - |
Danielle Campbell | F | - | 3 years | |
Pushkal Garg | M | 56 | 10 years | |
George W. Gray | M | - |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 13 years |
Steven A. Bossone | M | - | 14 years | |
Kristin Anne Torres Mowat | F | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Nigam Shah | M | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Diego Miralles | M | 62 |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Peter L. Masanotti | M | 69 |
Cureatr, Inc.
![]() Cureatr, Inc. Medical/Nursing ServicesHealth Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | - |
John J. Sokolowski | M | - |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 13 years |
Jo-Ann Beltramello | F | - | 17 years | |
Ria M. Carlson | F | 62 |
Hands Together
| - |
Todd Pietri | M | - |
Cureatr, Inc.
![]() Cureatr, Inc. Medical/Nursing ServicesHealth Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | 11 years |
Muthiah Manoharan | M | - | 21 years | |
John M. Douglass | M | - |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 12 years |
Wei Li | M | 52 |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | - |
Richard Heyman | M | 66 | - | |
Andrew B. Cubitt | M | - | 13 years | |
Alexa von Tobel | F | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
R. Alan B. Ezekowitz | M | 70 |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Ian D. Fier | M | - | 22 years | |
Ketan Patel | M | 49 |
Ivenix, Inc.
![]() Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | - |
Jill Broadfoot | F | 63 | 6 years | |
Alan Eisenberg | M | - | 7 years | |
Arnold Milstein | M | - |
CHP Management, Inc.
![]() CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
James Bilotta | M | - | 9 years | |
Lisa Carey | F | - | 9 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christoph Westphal | M | 56 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 9 years |
Craig Wheeler | M | 63 | 14 years | |
John Mendlein | M | 64 | 9 years | |
Marsha Fanucci | F | 70 | 18 years | |
Amir Nashat | M | 51 | - | |
John Maraganore | M | 60 | 19 years | |
Mike Mason | M | 49 | 14 years | |
Bruce Downey | M | 76 | 11 years | |
Grove Matsuoka | M | - | - | |
Susanna High | F | 56 | 9 years | |
Dinah Sah | M | 63 | 7 years | |
Elizabeth Stoner | M | 73 | 13 years | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Young Kwon | M | 52 | 10 years | |
Marcy Graham | F | 57 | - | |
Thomas Paul Koestler | M | 72 | 9 years | |
David Sinclair | M | 55 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Patricia Allen | F | 62 | 7 years | |
Frédéric Chéreau | M | 57 | 1 years | |
David-Alexandre Gros | M | 51 | 2 years | |
John Blake | M | 47 | 3 years | |
Stan Blackburn | M | 68 | - | |
Arianna Greco | M | - | - | |
Steven Paul | M | 73 | 12 years | |
Peter Barrett | M | 71 | 5 years | |
Ben Shapiro | M | 84 | 13 years | |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 years |
Barry Greene | M | 60 | 17 years | |
Laurie Keating | F | 70 | 7 years | |
Lisa Carron Shmerling | F | 63 | - | |
Manmeet Singh Soni | M | 46 | 2 years | |
James Blair | M | 84 | 10 years | |
James Sulat | M | 73 | 11 years | |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
![]() Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 years |
Ram Sasisekharan | M | 58 | 9 years | |
Peter Hutt | M | 89 | 13 years | |
Bruce A. Leicher | M | 68 | 10 years | |
Kevin Starr | M | 61 | 15 years | |
Victor J. Dzau | M | 78 | 7 years | |
Richard Shea | M | 72 | 13 years | |
Robert Langer | M | 74 | 8 years | |
Srini Akkaraju Akkaraju | M | 56 | 3 years | |
Svetlana Lucas | M | 52 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Clarke
- Personal Network